stockrow
Saturday 7 November 2026
Export INMB’s income statement to Excel — free account
INmune Bio, Inc.
INMB Healthcare Biotechnology
INmune Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50,000.00, up 257.1% from fiscal 2024.
- Revenue
- +8.70%
- EPS
- +95.2%
- Free cash flow
- +55.4%
Quarter to June 2026, against a year earlier
1.12
0.06
−5.08%
Follow INMB
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +35.4% | 10 | 10 | 24 | +682.0% | |
| Gross margin, % | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | 0 | (1) | (12) | (8) | (12) | (30) | (27) | (30) | (42) | (46) | (18) | +76.4% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | (109,990.91) | (16,762.43) | (7,299.20) | (19,360.00) | (300,685.71) | (91,866.00) | 0.00 | (91,866.0) pt | ||||||
| Net income | 0 | (1) | (12) | (8) | (12) | (30) | (27) | (30) | (42) | (46) | (18) | +76.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.02) | (0.13) | (1.43) | (0.75) | (1.01) | (1.88) | (1.52) | (1.67) | (2.11) | (1.86) | (0.67) | +65.5% | ||||||
| Cash flow | (0.03) | (0.12) | (0.24) | (0.52) | (0.75) | (1.77) | (1.27) | (0.67) | (1.67) | (0.91) | (0.56) | +47.1% | ||||||
| Capex | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 | (0.93) | 0.00 | 0.00 | 0.00 | (0.04) | (0.06) | n/m | ||||||
| Free cash flow | (0.03) | (0.13) | (0.24) | (0.52) | (0.75) | (2.70) | (1.27) | (0.67) | (1.67) | (0.95) | (0.61) | +47.8% | ||||||
| Book value | (0.01) | 2.76 | 1.91 | 2.30 | 3.23 | 4.97 | 3.35 | 2.08 | 1.61 | 0.95 | 0.76 | n/m | ||||||
| Shares, m | 11 | 7 | 9 | 10 | 12 | 16 | 18 | 18 | 20 | 25 | 26 | +9.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 857.41 | 321.63 | 1,301.59 | 710.98 | 286.09 | 221.67 | 579.6 | ||||||
| P/B | — | — | — | — | 5.33 | 2.05 | 2.00 | 5.40 | 2.90 | 1.64 | 1.47 | 3.2 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 543.28 | 221.48 | 1,149.65 | 588.45 | 138.83 | 121.37 | 440.3 | ||||||
| EV/FCF | — | — | — | — | (20.64) | (3.66) | (3.65) | (14.87) | (2.31) | (0.79) | (1.00) | (7.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 0 | (1) | (2) | (5) | (9) | (29) | (23) | (12) | (33) | (23) | (15) | +60.6% | |||||
| Capex | — | 0 | — | — | — | (15) | — | — | — | (1) | (1) | +34.0% | ||||||
| Free cash flow | 0 | (1) | (2) | (5) | (9) | (44) | (23) | (12) | (33) | (24) | (16) | +61.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 0 | 2 | 0 | 7 | 22 | 78 | 54 | 21 | 15 | 21 | 18 | n/m | |||||
| Net debt | 0 | (1) | 0 | (7) | (22) | (60) | (37) | (26) | (21) | (25) | (18) | n/m | ||||||
| Shareholders’ equity | 0 | 18 | 17 | 24 | 39 | 80 | 60 | 37 | 32 | 24 | 20 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (2.94) | (8.82) | (69.54) | (36.71) | (37.16) | (43.16) | (30.04) | (43.24) | (87.16) | (127.75) | (57.08) | (124.8) pt | |||||
| ROIC | 0.00 | (3.67) | (47.54) | (28.88) | (45.10) | (91.35) | (71.62) | (162.87) | (238.53) | 0.00 | (646.94) | 0.0 pt | ||||||
| ROE | (3.09) | (9.26) | (71.82) | (38.25) | (38.80) | (51.00) | (38.91) | (61.59) | (121.21) | (165.16) | (74.82) | (162.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 2 | 3 | 4 | 5 | 10 | 10 | 17 | 22 | 21 | — | +34.2% | |||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.04 | 0.01 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Mar 2025
INmune Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics Inc. | $35.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | Compare |
| VERU Veru Inc. | $35.1M | — (loss-making) | — (loss-making) | +99.23% (above 0%: growing) | n/m | +0.27% (above 0%: growing) | 67.84% | 0.00% | Compare |
| LIANY LianBio Sponsored ADR | $34.2M | 0.0× | — | — | n/m | +1,107.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRDX GridAI Technologies Corp. | $33.3M | — (loss-making) | — | — | n/m | −2,640.98% (below 0%: shrinking) | (42.49%) | (15,258.21%) | Compare |
| NNVC NanoViricides, Inc. | $32.9M | — (loss-making) | — | — | n/m | −23.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PMN Promis Neurosciences | $32.7M | — (loss-making) | — | 0.00% | n/m | −169.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| INMB INmune Bio, Inc. | $32.6M | — (loss-making) | — (loss-making) | +8.70% (above 0%: growing) | n/m | +55.39% (above 0%: growing) | 100.00% | 0.00% | |
| EYPT EyePoint, Inc. | $30.7M | — (loss-making) | — (loss-making) | −90.49% (below 0%: shrinking) | n/m | +0.41% (above 0%: growing) | 100.00% | (19,207.10%) | Compare |
| IRLA IRulya Therapeutics Inc. | $29.8M | — (loss-making) | — | — | n/m | −63.65% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $33.1M | — | — | 0.00% | — | −43.79% | 0.00% | 0.00% |